Canadian Cardiovascular Society

CCS-Pfizer ATTR-CM Research Fellowship Award

The Canadian Cardiovascular Society (CCS) and Pfizer have collaboratively created a research fellowship award entitled “CCS-Pfizer ATTR-CM Research Fellowship Award.”

This is a salary award where the purpose is to foster the growth of peer-reviewed Canadian research in the area of Transthyretin Amyloid Cardiomyopathy (ATTR-CM), with a focus on excellence and support for early career Canadian researchers familiar with diagnosing and treating patients with ATTR-CM who are looking to establish an independent research career.

2022 Call for Applications: Closed

Full details on the award and application process can be found in the CCS-Pfizer ATTR-CM Research Fellowship Award Handbook


Eligibility

  • Be a CCS Member. For more information about CCS Membership, visit the CCS website: http://www.ccs.ca/en/membership
  • Students, Trainees, Residents, Fellows, and Post Docs (including those who have completed an MD degree, PharmD, PhD, or equivalent). NOTE: Those with clinical or academic faculty positions are ineligible to apply as the primary applicant.
  • Have proof of a letter of acceptance to research or clinical position at a Canadian institution (or acceptance conditional on funding).
  • Applicants must be a Canadian Citizen or Permanent Resident of Canada.
  • Funded research must be conducted at a site in Canada associated with Canadian research institutions that are eligible to hold research funding (https://cihr-irsc.gc.ca/e/36374.html).
  • Applications for this award must be supported by the university or institution at which the applicant will conduct the proposed research program.

Eligible research activities must involve clinical outcomes research or clinical research in an area related to ATTR-CM, which may include the study of early identification, evaluation, diagnosis, prognosis and management; use of screening tools and their impact on improvement of patient health. The CCS, and all program partners, encourage all eligible CCS members to apply, especially women, Aboriginal peoples, persons with disabilities and members of visible minorities.

Ineligible Areas of Research

  • Head-to-head studies 
  • Any indications outside of TTR amyloidosis 
  • Pediatric investigations
  • End stage disease 
  • Dose response studies 
  • Tafamidis Animal studies 

The Award

A single salary award of $60,000 will be awarded to one individual based on an independent peer review process. Funding begins the summer of 2022 for 12 months.

The Peer Review Process

All applications will be pre-screened for eligibility. Applications that are late, incomplete and/or do not meet the basic eligibility criteria will be not be considered for review. Peer review of all eligible applications will be conducted by a scientific review committee comprised of CCS members. The 2022 peer review committee members are Dr. Margot Davis, Dr. Diego Delgado, Dr. Nowell Fine, and Dr. Jonathan Howlett. All eligible proposals will be reviewed by at least two members of the peer review committee. All applicants will receive notification of funding/non-funding and awards will be announced by June 30.

If you have any questions or require support preparing and submitting your application, please email researchawards@ccs.ca.


Supported by:

The Canadian Cardiovascular Society and Pfizer Canada are proud to support the CCS-Pfizer ATTR-CM Research Fellowship Award. With this award, we hope to support early career Canadian researchers familiar with diagnosing and treating patients with ATTR-CM who are looking to establish an independent research career.

Back to top